STAT

Buffalo gave us spicy wings and the ‘book of life.’ Here’s why that’s undermining personalized medicine

The human reference genome, largely completed in 2001, has achieved near-mythic status, but it falls short in ways that have become embarrassing and misleading.

The geneticists had high hopes of identifying the mutation that had caused the little boy’s abnormalities: a flattened face, cognitive delays, cleft palate, stubby thumbs, and a host of other skeletal malformations. They were pretty sure he had a rare disease called Baratela Scott syndrome, which had been identified only in 2012. But because its symptoms overlap with those of other hereditary disorders, they couldn’t be sure.

At the University of Washington, geneticists looked for a gene mutation that had been found in other children with the disorder. Following the usual procedure, they checked the spelling of the boy’s DNA sequences against the closest thing genomics has to a dictionary — the “reference” human genome, the grand product of the decade-long, $2.7 billion Human Genome Project.

To the scientists’ puzzlement, however, the boy’s sequence showed no sign of the mutation in the gene known to cause Baratela Scott, called XYLT1. Nor did the DNA of the next boy with the disorder, or the next. As they tried to compare the boys’ DNA sequences to the reference genome, it was like trying to check a spelling in a Webster’s from which a prankster had

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks